Bryan Johnson Blueprint Protocol Review (2026): What Is Transferable and What Is Not

Blueprint is Bryan Johnson's publicly documented personal health protocol. Johnson publishes the whole thing at protocol.bryanjohnson.com under a Creative Commons non-commercial license, which makes it unusually easy to review. The current version specifies 2,250 calories a day, described on the site as roughly 10 percent caloric restriction, split as 130 grams of protein, 206 grams of carbohydrate, and 101 grams of fat. It sets a fixed 8:30 pm bedtime and a wake time near 5:00 am, six hours of weekly exercise, a daily sauna, a long supplement stack, and a list of off-label prescriptions. It also documents therapies most readers will never access.

This review is for you if Blueprint made longevity feel urgent and you now want to know which parts have evidence behind them. It is not a takedown. Johnson does several things the outcome literature supports, and he does them with more consistency than almost anyone. The problem is presentation. The protocol lists interventions with decades of randomized human data and interventions with no human outcome data at all in the same format, at the same visual weight. Sorting them is the work. Copy the list top to bottom and you will spend most of your money and attention on the weakest tier.

Cost and access are real constraints here, not footnotes. The published protocol includes 60 hyperbaric oxygen sessions at 90 minutes each, a follistatin gene therapy administered in October 2023, 300 million mesenchymal stem cells injected into knees, hips, and shoulders in March 2024, and three months of daily intramuscular cerebrolysin. None of that is available at a normal budget or from a normal clinician in the United States. Treat that tier as a dispatch from an experiment you are not running. If you want the ordered version of what follows, alivelongevity.com/start-here.

Blueprint is a single-subject, uncontrolled, unblinded, non-randomized self-experiment in which dozens of variables change at once. That design cannot attribute any result to any input. If Johnson's vascular measurements improved, the cause could be the sauna, the training, the candesartan, the diet, the sleep schedule, body composition change, or measurement drift. There is no comparison arm and no way to separate them. This is not an attack on Johnson, who says roughly the same thing on his own site. It is a statement about what n=1 evidence supports. An n=1 protocol generates hypotheses. It does not test them.

The site's own caveat is more honest than most coverage of it. Blueprint states that its biological age claims are preliminary and can be influenced by statistical variation, reference range relevancy, and clinical outcome significance. That is the correct disclaimer. Hold every reported improvement to it. A 2.6 percent change in telomere length after 60 hyperbaric sessions is a laboratory number from one person across one pair of blood draws. It is not evidence that hyperbaric oxygen slows aging in you, and it is not evidence that it changes how long or how well you live.

Apply a four-tier filter to every item in the protocol. Tier one has randomized human trials with hard outcomes: death, heart attack, fracture, disability. Tier two has randomized human trials measuring biomarkers only. Tier three has observational associations, mechanistic reasoning, or animal data. Tier four is marketing. Nearly every Blueprint component you have heard discussed online sits in tiers two and three. The components that would actually move your mortality risk sit in tier one, and they are the least interesting ones to write about, which is precisely why they get the least coverage.

The transferable core is unglamorous. Structured aerobic training, resistance training, adequate protein, consistent sleep timing, blood pressure control, and lipid management carry the strongest evidence in the entire protocol, and none of it is proprietary to Blueprint. Johnson's exercise prescription is six hours a week: three strength sessions and three cardio sessions, with 150 minutes at moderate intensity and 75 minutes at vigorous intensity. That is roughly double the public health minimum, which asks for 150 minutes of moderate activity or 75 minutes of vigorous activity a week, not both; Blueprint lands near the top of the recommended range rather than past it. It is in the protocol not because it is exotic but because it is the part that reliably works.

Cardiorespiratory fitness is the most defensible target on the list. In a retrospective cohort of 122,007 adults referred for treadmill testing, the highest-performing group had roughly 80 percent lower all-cause mortality than the lowest, with no observed upper limit of benefit. That is observational, so it cannot prove causation, and fitness partly reflects underlying health rather than training alone. But the effect size dwarfs anything in the supplement or device tiers, and the intervention costs nothing. If you take one thing from Blueprint, take the training volume. VO2 Max Training for Longevity: High-Impact Programming Without Burnout covers how to build it.

Sleep timing deserves equal attention and gets less. Blueprint fixes bedtime at 8:30 pm and takes the final meal at noon, roughly eight and a half hours before sleep. You do not need those clock times. What transfers is regularity: the same sleep window seven days a week, weekends included. Blueprint's version is extreme in that it subordinates evening social life entirely, a trade most people will not make and probably should not. Pick a window you can hold for 90 days rather than the earliest one you can imagine holding for a week.

The prescription tier is where the protocol diverges hardest from anything you should copy. Blueprint lists metformin at 500 mg on six-week on-off cycles, acarbose, empagliflozin at 10 mg, candesartan at 8 mg, evolocumab at 140 mg every other week, oral minoxidil at 3.75 mg, and thyroid replacement for a hypothyroidism diagnosis Johnson has carried since age 21. These are real drugs with real indications. Every one of them, and the rapamycin discussed below, is prescription-only in the United States and needs a clinician who knows your history and is monitoring you; the doses above are Johnson's record, not a recommendation. The antihypertensive and the lipid-lowering agent have randomized cardiovascular outcome evidence in appropriate patients. The rest are being used off-label against aging, which is a different question with a much thinner answer.

Metformin is the clearest case of enthusiasm outrunning evidence. It is a well-characterized diabetes drug with decades of safety data. No randomized trial has reported lifespan or healthspan outcomes for metformin in people without diabetes. There is also a direct conflict with the exercise half of the protocol. In a double-blind randomized trial of 53 older adults at risk for diabetes, metformin titrated to 2,000 mg daily, or 1,500 mg for participants under 75 kg, abolished the mitochondrial adaptation to 12 weeks of aerobic training, and attenuated the gain in cardiorespiratory fitness by about half, a difference that did not reach statistical significance. If your plan is to raise VO2 max and take metformin, read Metformin for Longevity: Pros, Cons, and Decision Criteria first.

Rapamycin is instructive because Johnson dropped it. He tested weekly 5, 6, and 10 mg doses plus biweekly and alternating schedules across almost five years, then discontinued, citing intermittent skin and soft tissue infections, lipid abnormalities, glucose elevations, and a higher resting heart rate. The published human data points the same direction. The PEARL trial followed 114 healthy adults aged 50 to 85 through 48 weeks of placebo or 5 or 10 mg of compounded rapamycin weekly. Overall adverse events were comparable across arms, though gastrointestinal symptoms were about twice as common on rapamycin. The primary endpoint, visceral adiposity, did not change. That is a safety result, not an efficacy result.

Hyperbaric oxygen has the most confident marketing and the least outcome data. Blueprint's protocol is 100 percent oxygen at two atmospheres, 90 minutes per session, five sessions a week for 60 sessions. The study most often cited for anti-aging HBOT used that same protocol in 35 adults aged 64 and older. It had no control group. It measured telomere length in isolated blood cells and the proportion of senescent T cells, and it measured no clinical outcomes at all. The percentage changes in those cell markers were large. Nobody has shown that moving them changes how you age. See Hyperbaric Oxygen Therapy for Longevity: Protocols, Evidence, and Where It Stops.

Senolytics are a staple of the broader longevity-influencer stack rather than a listed part of Blueprint's published protocol, and they sit in the same evidentiary position. The first-in-human study of dasatinib plus quercetin enrolled 14 patients with idiopathic pulmonary fibrosis and gave 100 mg dasatinib with 1,250 mg quercetin on three consecutive days a week for three weeks. Walking distance and chair-stand time improved. Lung function did not. The authors stated plainly that without a control arm the functional improvements must be interpreted with caution. That is nine days of drug exposure in fourteen sick patients, not a basis for a healthy adult to self-administer dasatinib, a prescription chemotherapy drug, outside a trial.

The remaining device and biologic tier is where the evidence runs out entirely. The stem cell, gene therapy, and cerebrolysin interventions listed earlier, plus shockwave therapy at 4,500 shocks three days a week and a 655 nm red light cap worn six minutes a day, share one property: no randomized trial has shown that any of them slows aging, extends healthspan, or reduces mortality in humans. Some have plausible mechanisms. Some have evidence in narrow clinical indications unrelated to aging, which is not the same thing as evidence for aging. Anti-aging stem cell therapy in particular is largely sold outside approved indications. Spend here last, if ever.

Blueprint's measurement layer is its most genuinely novel contribution, and also where interpretation gets slippery. The protocol runs blood draws every three to six months, an annual full-body MRI, daily body composition, continuous glucose monitoring, and multispectral skin imaging. Johnson describes himself as the most biologically measured person ever, which is plausibly true. Dense measurement is a real advantage: it catches drift early and it makes adherence visible rather than remembered. The failure mode is treating every measured variable as a target and every fluctuation as a signal worth acting on.

Understand what a pace-of-aging score actually is. DunedinPACE, the best-validated of them, was built by tracking within-individual decline across 19 indicators of organ-system integrity at four time points spanning two decades in a single birth cohort, then distilling that trajectory into a DNA methylation test. It predicts morbidity, disability, and mortality at the group level, which makes it a useful research instrument. It does not make it a scoreboard. No trial has shown that deliberately lowering your score produces longer life or better function. Biological Age Testing: The Complete Guide to Epigenetic Clocks, At-Home Tests, and What the Results Actually Mean explains how the available clocks differ.

For your own protocol, a much smaller panel does more work. Blood pressure, ApoB or LDL-C, HbA1c or fasting insulin, hs-CRP, and a resting heart rate trend will tell you more about your trajectory than any consumer aging clock. Those markers have treatment thresholds, established interventions, and outcome data behind them. An epigenetic age result has none of the three. If a number does not change a decision you would actually make, measuring it more often is a hobby rather than a protocol. Frequency is not the same thing as information.

Here is how to adapt the transferable tier without importing the complexity. Weeks one and two: change nothing except measurement. Get a baseline blood panel, take three morning blood pressure readings on separate days, record your current training volume honestly, and fix a sleep window you can hold seven days a week. You cannot evaluate an intervention against a baseline you never took. Most people skip this step and then spend the next year arguing with themselves about whether something worked. Best Longevity Blood Tests to Track in 2026: A Clinically Useful Panel covers which panel to order.

Weeks three through eight: build the training and the food structure, and change nothing else. Three resistance sessions and three cardio sessions a week, with most cardio at conversational intensity and one shorter hard session. Set a deliberate daily protein target instead of taking whatever the day gives you. Build one repeatable default meal, which is the actual mechanism behind Blueprint's rigid menu rather than the specific ingredients. Add at most one supplement in this window, so any change in how you feel has a single candidate cause.

Weeks nine through twelve: hold the protocol and retest. Use the same blood panel, the same blood pressure method, the same training benchmark. Judge direction across the whole block rather than single values, because assay variation and normal day-to-day biology move most markers a few percent for no reason. If your adherence was below roughly 80 percent, you tested adherence rather than the protocol, and the correct response is to make the protocol smaller. Adding interventions to a protocol you are not completing is the most common way this fails.

Several parts of Blueprint carry real risk, unevenly distributed. Every prescription in the protocol requires a prescriber who knows your history. Acarbose, empagliflozin, metformin, candesartan, and thyroid hormone each have contraindications, interactions, and monitoring requirements, and thyroid replacement in particular is for a diagnosed condition rather than an optimization lever. Oral minoxidil has cardiovascular effects. Hyperbaric oxygen has one absolute contraindication, untreated pneumothorax, plus a long list of relative ones including pregnancy, epilepsy, certain ear, sinus, and lung conditions, and treatment with bleomycin, doxorubicin, or cisplatin. Active or prior cancer is its own gate on the advanced tier: dasatinib is a prescription chemotherapy drug, and anti-aging stem cell injection is sold outside approved indications, so neither belongs in a self-directed protocol for anyone with a cancer history. None of this is safely self-directed. If you are pregnant, trying to conceive, managing a chronic condition, or taking regular medication, this article is a reading list for a clinician visit, not a plan.

Johnson's own data illustrates a specific hazard worth naming. His site reports that a run of sauna sessions without groin cooling coincided with large drops in sperm motile count, motility, and normal morphology, and that adding an ice pack during sessions reversed the pattern. Heat exposure and male fertility interact, and that is exactly the kind of side effect a dense measurement layer catches and a casual protocol never sees. If you are running regular heat exposure and trying to conceive, that interaction belongs in the conversation before you start, not after.

The dominant failure mode is not danger. It is dilution. People adopt fifteen low-evidence interventions, exhaust their attention in six weeks, and abandon the four that would have mattered. Set stop criteria before you start. Any intervention that has not moved a target marker or a clear subjective measure in 12 weeks gets dropped. Any week where sleep or recovery degrades, you subtract rather than add. Blueprint is worth reading as a published, falsifiable, unusually transparent experiment. It is worth copying only in the places where the evidence would exist without it.